Adenoviral-delivered angiopoietin-1 reduces the infarction and attenuates the progression of cardiac dysfunction in the rat model of acute myocardial infarction.

In acute myocardial infarction (AMI), prognosis and mortality rate are closely related to the infarct size and the progression of postinfarction cardiac failure. Angiogenic gene therapy has presented a new approach for the treatment of AMI. Angiopoietin-1 (Ang1) is a critical angiogenic factor for vascular maturation and enhances vascular endothelial growth factor (VEGF)-induced angiogenesis in a complementary manner. We hypothesized that gene therapy using Ang1 for AMI might promote angiogenesis cooperatively with intrinsic VEGF, since high concentrations of circulating VEGF have been reported in AMI. To evaluate our hypothesis, we employed a rat AMI model and adenoviral Ang1 (HGMW-approved gene symbol ANGPT1) gene transfer to the heart. A significant increase in capillary density and reduction in infarct sizes were noted in the infarcted hearts with adenoviral Ang1 gene treatment compared with control infarcted hearts treated with saline or adenoviral vector containing the beta-galactosidase gene. Furthermore, the Ang1 group showed significantly higher cardiac performance in echocardiography (55.0% of ejection fraction, P < 0.05 vs control) than the saline or adenoviral controls (36.0 or 40.5%, respectively) 4 weeks after myocardial infarction. The adenoviral delivery of Ang1 during the acute phase of myocardial infarction would be feasible to attenuate the progression of cardiac dysfunction in the rat model.

[1]  Thomas N. Sato,et al.  Leakage-resistant blood vessels in mice transgenically overexpressing angiopoietin-1. , 1999, Science.

[2]  F. Sellke,et al.  Enhanced microvascular relaxations to VEGF and bFGF in chronically ischemic porcine myocardium. , 1996, The American journal of physiology.

[3]  H. Hamada,et al.  Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors. , 2002, Human gene therapy.

[4]  L. Kedes,et al.  Adenovirus-mediated gene transfer into infarcted myocardium: feasibility, timing, and location of expression. , 1996, Journal of molecular and cellular cardiology.

[5]  Pamela F. Jones,et al.  Isolation of Angiopoietin-1, a Ligand for the TIE2 Receptor, by Secretion-Trap Expression Cloning , 1996, Cell.

[6]  E. Braunwald,et al.  Topographic changes in the left ventricle after experimentally induced myocardial infarction in the rat. , 1983, The American journal of cardiology.

[7]  N. Taichman,et al.  Human neutrophils secrete vascular endothelial growth factor , 1997, Journal of leukocyte biology.

[8]  H. Niwa,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector. , 1991, Gene.

[9]  J. Isner.  Myocardial gene therapy , 2002, Nature.

[10]  H. Dvorak,et al.  Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. , 1992, Molecular biology of the cell.

[11]  A. van der Eb,et al.  A new technique for the assay of infectivity of human adenovirus 5 DNA. , 1973, Virology.

[12]  S. Rafii,et al.  Vascular Endothelial Growth Factor and Angiopoietin-1 Stimulate Postnatal Hematopoiesis by Recruitment of Vasculogenic and Hematopoietic Stem Cells , 2001, The Journal of experimental medicine.

[13]  I. Sjaastad,et al.  Echocardiographic criteria for detection of postinfarction congestive heart failure in rats. , 2000, Journal of applied physiology.

[14]  H. Wakimoto,et al.  Adoptive immunotherapy with murine tumor-specific T lymphocytes engineered to secrete interleukin 2. , 1994, Cancer research.

[15]  H. Hamada,et al.  Pre‐administration of angiopoietin‐1 followed by VEGF induces functional and mature vascular formation in a rabbit ischemic model , 2003, The journal of gene medicine.

[16]  Y. Kaneda,et al.  Cell Transplantation for the Treatment of Acute Myocardial Infarction Using Vascular Endothelial Growth Factor–Expressing Skeletal Myoblasts , 2001, Circulation.

[17]  J. Isner,et al.  Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. , 1998, Journal of vascular surgery.

[18]  A. Hara,et al.  Lack of (cid:1) 2-antiplasmin promotes pulmonary heart failure via overrelease of VEGF after acute myocardial infarction , 2022 .

[19]  K Walsh,et al.  Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. , 1998, Circulation.

[20]  G. Koh,et al.  Gene therapy for gastric ulcers with single local injection of naked DNA encoding VEGF and angiopoietin-1. , 2001, Gastroenterology.

[21]  Thomas N. Sato,et al.  Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation , 1995, Nature.

[22]  F. Sellke,et al.  Expression of vascular endothelial growth factor and its receptors is increased, but microvascular relaxation is impaired in patients after acute myocardial ischemia. , 2001, The Journal of thoracic and cardiovascular surgery.

[23]  J. Chae,et al.  Coadministration of Angiopoietin-1 and Vascular Endothelial Growth Factor Enhances Collateral Vascularization , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[24]  E. Keshet,et al.  Upregulation of vascular endothelial growth factor expression induced by myocardial ischaemia: implications for coronary angiogenesis. , 1994, Cardiovascular research.

[25]  M. Gertsenstein,et al.  Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo. , 1994, Genes & development.

[26]  J. Isner,et al.  Gene Therapy with Vascular Endothelial Growth Factor for Inoperable Coronary Artery Disease: Anesthetic Management and Results , 2001, Anesthesia and analgesia.

[27]  M. Siemionow,et al.  Gene therapy by adenovirus-mediated vascular endothelial growth factor and angiopoietin-1 promotes perfusion of muscle flaps. , 2002, Plastic and reconstructive surgery.

[28]  Yamamura Ken-ichi,et al.  Efficient selection for high-expression transfectants with a novel eukaryotic vector , 1991 .

[29]  G. Thurston.  Complementary actions of VEGF and Angiopoietin‐1 on blood vessel growth and leakage * , 2002, Journal of anatomy.

[30]  J. Isner,et al.  Lower-Extremity Edema Associated with Gene Transfer of Naked DNA Encoding Vascular Endothelial Growth Factor , 2000, Annals of Internal Medicine.

[31]  N. Glazer,et al.  Angiopoietin-1 protects the adult vasculature against plasma leakage , 2000, Nature Medicine.

[32]  L. Brown,et al.  VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. , 1996, The American journal of physiology.

[33]  M. Pfeffer,et al.  Myocardial Infarct Size and Ventricular Function in Rats , 1979, Circulation research.

[34]  D. Thickett,et al.  Vascular endothelial growth factor may contribute to increased vascular permeability in acute respiratory distress syndrome. , 2001, American journal of respiratory and critical care medicine.

[35]  M. Kaur,et al.  Platelet-Derived Growth Factor-AB Limits the Extent of Myocardial Infarction in a Rat Model: Feasibility of Restoring Impaired Angiogenic Capacity in the Aging Heart , 2002, Circulation.

[36]  Y. Kanegae,et al.  Efficient generation of recombinant adenoviruses using adenovirus DNA-terminal protein complex and a cosmid bearing the full-length virus genome. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[37]  C. Frelin,et al.  Hypoxia is a strong inducer of vascular endothelial growth factor mRNA expression in the heart. , 1993, Biochemical and biophysical research communications.

[38]  J. Isner,et al.  Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia. , 1998, Circulation.

[39]  J. Isner,et al.  Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization. , 1998, Circulation research.

[40]  M. Post,et al.  Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease. , 1999, Circulation.

[41]  H. Hamada,et al.  Myocardial injection of CA promoter‐based plasmid mediates efficient transgene expression in rat heart , 2003, The journal of gene medicine.

[42]  P. Shabram,et al.  Sensitivity and reproducibility in adenoviral infectious titer determination , 1997, Nature Medicine.

[43]  S. Sugano,et al.  Efficient gene activation in mammalian cells by using recombinant adenovirus expressing site-specific Cre recombinase. , 1995, Nucleic acids research.

[44]  Federica Limana,et al.  Mobilized bone marrow cells repair the infarcted heart, improving function and survival , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[45]  J. Isner,et al.  Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease. , 1999, The Annals of thoracic surgery.

[46]  R. Weisel,et al.  Enhanced Myocardial Angiogenesis by Gene Transfer With Transplanted Cells , 2001, Circulation.

[47]  Y. Yazaki,et al.  Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy. , 1997, Clinical science.

[48]  R. Crystal,et al.  Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. , 2000, American journal of respiratory cell and molecular biology.

[49]  J. Isner,et al.  Somatic gene therapy in the cardiovascular system. , 2001, Annual review of physiology.

[50]  L. Kedes,et al.  Evaluation of the effects of intramyocardial injection of DNA expressing vascular endothelial growth factor (VEGF) in a myocardial infarction model in the rat--angiogenesis and angioma formation. , 2000, Journal of the American College of Cardiology.